Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market

Deep News01-27

On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to address unmet and differentiated clinical needs in the global market. The company consistently adheres to an open cooperation strategy, actively exploring business development opportunities for its innovative drug pipeline with global peers while strengthening its internal R&D capabilities. Should any definitive cooperation agreements be reached in the future, the company will strictly comply with information disclosure regulations to fulfill its disclosure obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117243250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117243250","market":"us","top_or_hot":-1,"title":"Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market","media":"Deep News","content":"<p>On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to address unmet and differentiated clinical needs in the global market. The company consistently adheres to an open cooperation strategy, actively exploring business development opportunities for its innovative drug pipeline with global peers while strengthening its internal R&D capabilities. Should any definitive cooperation agreements be reached in the future, the company will strictly comply with information disclosure regulations to fulfill its disclosure obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-27 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to address unmet and differentiated clinical needs in the global market. The company consistently adheres to an open cooperation strategy, actively exploring business development opportunities for its innovative drug pipeline with global peers while strengthening its internal R&D capabilities. Should any definitive cooperation agreements be reached in the future, the company will strictly comply with information disclosure regulations to fulfill its disclosure obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLP","symbol_name":"Global Partners Lp","start_time":0,"source_url":"","article_id":"1117243250","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117243250","pubTimestamp":1769514072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLP":"Global Partners Lp","BK0209":"零售","BK0183":"MSCI概念","BK0132":"高送转概念","BK4590":"PTP","BK0188":"融资融券","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0196":"行业龙头","BK0175":"白马股","000963":"华东医药","BK0187":"一线龙头","BK4144":"石油与天然气的储存和运输"},"translate_title":"华东医药：HDM1002作为差异化口服GLP-1靶向药物，定位于满足全球市场未被满足的差异化临床需求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"000963":1},"content_text":"On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to address unmet and differentiated clinical needs in the global market. The company consistently adheres to an open cooperation strategy, actively exploring business development opportunities for its innovative drug pipeline with global peers while strengthening its internal R&D capabilities. Should any definitive cooperation agreements be reached in the future, the company will strictly comply with information disclosure regulations to fulfill its disclosure obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117243250","isCrawlerRequest":true}